A Multi-national, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the Prevention of COVID-19 in Healthy Adults Aged 18 Years and Older
Latest Information Update: 05 Apr 2023
At a glance
- Drugs COVID-2019 vaccine-Shenzhen Kangtai Biological Products (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Shenzhen Kangtai Biological Products
- 26 Apr 2021 New trial record